In silico molecular mechanism of cannabigerol as a cyclooxygenase-2 inhibitor

  • Muhammad Abdullah Shah Department of Pharmacy, Sarhad University of Science and Information Technology, Peshawar
  • Syed Muhammad Abdullah Department of Computer Science, Islamia College University, Peshawar
  • Muhammad Azim Khan Department of Weed Science, The University of Agriculture, Peshawar
  • Hazrat Amin Institute of Chemical Sciences, University of Peshawar, Peshawar
  • . Roohullah Department of Pharmacy, Abasyn University, Peshawar
Keywords: COX-2 enzyme, Docking, Inflammation

Abstract

Discovery of new cyclooxygenase-2(COX-2) inhibitors is a major area in anti-inflammatory drug discovery. Cannabigerol is a cannabinoid, which is recently discovered as a new COX-2 inhibitor. So far no work has been done to explore in depth mechanistic insights to understand its mechanism and binding mode. In the current investigation, molecular docking simulations were performed to explore its binding mode and is molecular interactions with the ligand binding site of COX-2 enzyme. Cannabigerol showed multiple molecular contacts with active of COX-2 especially withArg120, Tyr355, and Met522. Hydrogen bonding, dipole-dipole and hydrophobic interactions were the key attractive forces involved in macromolecular contacts. Molecular modifications in Cannabigerol are discussed, which can lead to further improvement of the ligand as a new lead compound against COX-2 enzyme.

Downloads

Download data is not yet available.
Abstract
1714
Download
610 Read
81

References

Chen QH, Rao PN, Knaus, EE. Design, synthesis, and biological evaluation of N-acetyl-2-carboxybenzene sulfonamides: A novel class of cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med Chem. 2005; 13: 2459-68.

Crofford LJ. COX-1 and COX-2 tissue expression: Implications and predictions. J Rheumatol. 1997; 24: 15-19.

Habeeb AG, Praveen PN, Knaus, EE. Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygen-ase-2 (COX-2) inhibitors: Replacement of sulfonamide and methylsulfonyl pharmacophores by an azidobioisostere. J Med Chem. 2001; 44: 3039-42.

McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999; 96: 272-77.

Needleman P, Isakson P. The discovery and function of COX-2. J Rheumatology 1997; 24: 6-8.

O"Banion MK, Sadowski HB, Winn V, Young DA. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Bio Chem. 1991; 266: 23261-67.

Picot D, Loll PI, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994; 367: 243-49.

Rehman UU, Shah J, Khan MA, Shah MR, Khan I. Molecular docking of taraxerol acetate as a new COX inhibitor. Bangladesh J Pharmacol. 2013; 8: 194-97.

Selvam C, Jachak, SM, Thilagavathi, R, Chakraborti AK. Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. Bioorg Med Chem Lett. 2005; 15: 1793-97.

Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol. 1971; 231: 232-35.

Zogopoulos P, Vasileiou I, Patsouris E, Theocharis SE. The role of endocannabinoids in pain modulation. Fund Clin Pharmacol. 2013; 27: 64-80.

Published
2013-12-18
How to Cite
Shah, M., Abdullah, S., Khan, M., Amin, H., & Roohullah, . (2013). In silico molecular mechanism of cannabigerol as a cyclooxygenase-2 inhibitor. Bangladesh Journal of Pharmacology, 8(4), 410-413. https://doi.org/10.3329/bjp.v8i4.16617
Section
Research Articles

Most read articles by the same author(s)